Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.
The main objectives of this clinical trial are to determine the following:
* Does VIM0423 therapy improve dystonia symptoms compared to placebo?
* Is VIM0423 well tolerated in individuals with isolated dystonia? and
* Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Protocol Amendment History
6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-12-23; most recent amendment 2026-06-11.
Status change: Not Yet Recruiting → Recruiting2026-03-09